Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model

MLA

Cely S. Abboud, et al. “Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model.” Clinical Pharmacology & Therapeutics, vol. 109, Mar. 2021, pp. 1074–80. EBSCOhost, https://doi.org/10.1002/cpt.2197.

APA

Cely S. Abboud, Gauri G. Rao, Patrick O. Hanafin, John K. Diep, Keith S Kaye, Estefany Garcia, Jian Li, Tony Velkov, & Rajnikant Sharma. (2021). Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model. Clinical Pharmacology & Therapeutics, 109, 1074–1080. https://doi.org/10.1002/cpt.2197

Chicago

Cely S. Abboud, Gauri G. Rao, Patrick O. Hanafin, John K. Diep, Keith S Kaye, Estefany Garcia, Jian Li, Tony Velkov, and Rajnikant Sharma. 2021. “Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model.” Clinical Pharmacology & Therapeutics 109 (March): 1074–80. doi:10.1002/cpt.2197.